MIMETAS Receives Funding For Kidney-On-A-Chip
News Sep 11, 2014
The organ-on-a-chip company MIMETAS has received 1.6 million USD funding for development of a kidney-on-a-chip for toxicological applications. MIMETAS will collaborate in a consortium with Radboudumc (Nijmegen, The Netherlands) and FHNW (Basel, Switzerland). A panel of experts from GlaxoSmithKline, Pfizer, Roche, NC3Rs and renowned academic institutions has selected MIMETAS’ solution from a strong line-up of competing technologies.
The funding is awarded in the context of the NephroTube CRACK IT Challenge to support development of a microfluidic renal model, predicting renal toxicity during pre-clinical development. The consortium will use the funds to develop, analyze and validate a high-throughput kidney-on-a-chip model by combining MIMETAS’ OrganoPlate™ 3D-culturing technology with the human renal cell line ciPTEC™. The resulting model will be used to detect renal tubular injury observed in drug-induced nephrotoxicity. The model’s early prediction of nephrotoxicity will help to reduce animal experiments.
Novel Chip Developed for Fast and Accurate Disease Detection at Low CostNews
Innovative microfluidic chip uses only standard lab microscope to spot nano-biomolecules without any fluorescent labels.READ MORE